-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Downgrades Pacific Biosciences to Underweight, Lowers Price Target to $1.5

Benzinga·03/06/2026 14:04:09
Listen to the news
Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to Underweight and lowers the price target from $2 to $1.5.